Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases. Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum’s core capabilities include clinical development and in-house manufacturing expertise, specifically in process development and assay development.
Adverum Biotechnologies NASDAQ:
06/20/19 9:34 AM EDT
Data provided by Nasdaq.
Minimum 15 minutes delayed.
- Jun 10 2019
Summary ToggleAdverum Biotechnologies Doses First Patient in Second Cohort of OPTIC Phase 1 Clinical Trial of ADVM-022 Gene Therapy for Wet AMD
- May 16 2019
Summary ToggleAdverum Biotechnologies Provides Update on OPTIC Phase 1 Trial for ADVM-022 in Wet AMD
- May 8 2019
Summary ToggleAdverum Biotechnologies Reports First Quarter 2019 Financial Results and Provides Corporate Update
- May 2 2019
Summary ToggleAdverum Biotechnologies Announces Board Changes
There are currently no events to display.